About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Systemic Diseases group performs translational research based on at least 300 patients with systemic lupus erytomatosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, vasculitis, dermatomyitis, Sjörgen syndrome or autoinflammatory syndromes in order to better understand their pathogenesis (both at the immunological and genetic regulation level), study their clinical and biological expression (through the detection of new markers that help characterize each of the autoimmune diseases), study morbimortality (through epidemiological studies) and analyse patients' response to medications. With these goals in mind, we seek to improve the diagnosis, clinical monitoring, and prognosis of our patients.
PMID: 33831619 Journal: Journal of Allergy and Clinical Immunology-In Practice Year: 2021 Reference: J Allergy Clin Immunol Pract. 2021 Jun;9(6):2284-2292. doi: 10.1016/j.jaip.2021.03.038. Epub 2021 Apr 5. Impact factor: 8.861 Publication type: Paper in international publication Authors: Sabate-Bresco, Marina, Rodriguez-Garijo, Nuria, Azofra, Julian, Baeza, Maria Luisa, Donado, Carmen Diaz, Gaig, Pere, Guilarte, Mar, Herrera-Lasso, Valeria, Labrador-Horrillo, Moises, Sala-Cunill, Anna et al. DOI: 10.1016/j.jaip.2021.03.038
PMID: 33831620 Journal: Journal of Allergy and Clinical Immunology-In Practice Year: 2021 Reference: J Allergy Clin Immunol Pract. 2021 Jul;9(7):2844-2852.e5. doi: 10.1016/j.jaip.2021.03.037. Epub 2021 Apr 5. Impact factor: 8.861 Publication type: Paper in international publication Authors: Wagner, Nicola, Wedi, Bettina, Wenzel, Markus, Bilo, Maria Beatrice, Worm, Margitta, Bauer, Andrea, Kreft, Burkhard, Cardona, Victoria, Kraft, Magdalena, Dolle-Bierke, Sabine et al. DOI: 10.1016/j.jaip.2021.03.037
PMID: 33811358 Journal: ALLERGY Year: 2021 Reference: Allergy. 2021 Oct;76(10):2952-2964. doi: 10.1111/all.14838. Impact factor: 13.146 Publication type: Paper in international publication Authors: Bosnic-Anticevich, Sinthia, Agache, Ioana, Blain, Hubert, Jutel, Marek, Ventura, Maria Teresa, Worm, Margitta, Del Giacco, Stefano, Benetos, Athanasios, Bilo, M Beatrice, Czarlewski, Wienczyslawa et al. DOI: 10.1111/all.14838
PMID: 32423687 Journal: MEDICINA CLINICA Year: 2021 Reference: Med Clin (Barc). 2021 Apr 9;156(7):362-363. doi: 10.1016/j.medcli.2020.01.040. Epub 2020 May 16. Impact factor: 1.725 Publication type: Letter or abstract Authors: Vega-Cano, Sharela, Cordero-Vazquez, Efrain, Mestre-Torres, Jaume et al. DOI: 10.1016/j.medcli.2020.01.040
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.
It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.
